Here are the 10-K annual reports from RxSight, Inc. (RXST) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RXST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXST filings page.
RxSight, Inc. is a commercial-stage medical technology company focused on premium cataract surgery through its proprietary RxSight Light Adjustable Lens system, which lets surgeons customize a patient’s vision after cataract surgery using ultraviolet light adjustments.
The system combines the Light Adjustable Lens with an office-based Light Delivery Device and has been designed to address key limitations of non-adjustable premium intraocular lenses, such as preoperative guesswork and limited ability to correct residual refractive error. As of December 31, 2025, RxSight had an installed base of 1,134 Light Delivery Devices and surgeons had implanted approximately 300,000 Light Adjustable Lenses since inception.
Management highlights a large and growing opportunity: about 5.2 million cataract surgeries in the U.S. in 2025 and an estimated $860 million U.S. premium IOL market, projected to grow at an 11% CAGR through 2030. The company emphasizes strong clinical data, including higher rates of 20/20 uncorrected vision versus leading toric lenses, and reports research and development expenses of $38.5 million in 2025 as it continues to enhance the system and expand indications. RxSight states it believes its current cash, cash equivalents and short-term investments will fund operations for at least the next 12 months and does not anticipate needing to raise additional capital or incur additional debt to reach profitability from operations, while noting it may opportunistically raise capital to support expansion.